ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ANIX Anixa Biosciences Inc

2.60
0.24 (10.17%)
Jun 07 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 223,992
Bid Price 2.60
Ask Price 2.65
News (2)
Day High 2.65

Low
2.21

52 Week Range

High
5.13

Day Low 2.3501
Share Name Share Symbol Market Stock Type
Anixa Biosciences Inc ANIX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.24 10.17% 2.60 18:18:43
Open Price Low Price High Price Close Price Previous Close
2.40 2.3501 2.65 2.55 2.36
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
1,152 223,992 US$ 2.50 US$ 559,339 - 2.21 - 5.13
Last Trade Type Quantity Price Currency
16:05:15 76 US$ 2.60 USD

Anixa Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
80.39M 31.90M - 210k -9.81M -0.31 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Anixa Biosciences News

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ANIX Message Board. Create One! See More Posts on ANIX Message Board See More Message Board Posts

Historical ANIX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.532.652.212.4567,5940.072.77%
1 Month2.893.042.212.6478,067-0.29-10.03%
3 Months3.154.102.213.12104,100-0.55-17.46%
6 Months4.025.132.213.79152,566-1.42-35.32%
1 Year3.535.132.213.67114,150-0.93-26.35%
3 Years4.126.452.214.04115,080-1.52-36.89%
5 Years4.348.091.333.79190,122-1.74-40.09%

Anixa Biosciences Description

Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer.